Ngenla Market Report 2026

Ngenla Market Overview

• The Ngenla market growth in the historic period has been driven by improved diagnosis rates of growth hormone deficiency, established use of daily somatropin therapies • Market expansion is supported by rising demand for long-acting endocrine therapies, increasing adult ghd diagnosis rates • Growth Driver: Rising Prevalence Of Pediatric GHD Drives Growth In The Market • Market Trend: Advancements In Long-Acting Growth Hormone Therapies To Improve Treatment Adherence And Patient Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ngenla Market?

Ngenla refers to a long-acting human growth hormone (somatrogon) developed for the treatment of growth hormone deficiency (GHD) in children and adults. It is used to improve growth and manage growth-related disorders by replacing the natural growth hormone in individuals with inadequate production. The main indication types of ngenla are growth hormone deficiency, turner syndrome, prader-willi, and small for gestational age. Growth hormone deficiency is a condition where the body does not produce enough growth hormone, leading to poor growth in children and adults. The several distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies, and it is used by various end users such as pediatric patients and adult patients.

What Is The Ngenla Market Growth Forecast?

The growth in the forecast period can be attributed to rising demand for long-acting endocrine therapies, increasing adult ghd diagnosis rates, growing focus on quality-of-life outcomes, expansion of biologics manufacturing capacity, stronger payer support for innovative hormone treatments. Major trends in the forecast period include increasing adoption of long-acting growth hormone therapies, rising preference for reduced injection frequency treatments, growing focus on patient adherence improvement, expansion of recombinant hormone manufacturing capabilities, enhanced emphasis on personalized endocrine care.

Global Ngenla Market Segmentation

1) By Indication: Growth Hormone Deficiency, Turner Syndrome, Prader-Willi, Small For Gestational Age 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Pediatric Patients, Adult Patients

What Is The Driver Of The Ngenla Market?

The increasing prevalence of pediatric growth hormone deficiency (GHD) is expected to drive the ngenla market going forward. Pediatric GHD is a condition characterized by inadequate secretion of growth hormone, which can impact physical development and overall health in children. The prevalence of GHD is rising due to improved awareness, enhanced diagnostic capabilities, and increased access to healthcare services globally. Ngenla, a long-acting recombinant human growth hormone (somatrogon), helps pediatric growth hormone deficiency by providing a sustained and consistent release of growth hormone through once-weekly injections, reducing the treatment burden of daily administration, improving adherence, and effectively stimulating growth and development in children with inadequate growth hormone production. For instance, in January 2024, according to the National Library of Medicine (NLM), a US-based biomedical library, growth hormone deficiency (GHD) is a rare condition in children, with its prevalence estimated to range from 1 in 3,500 to 1 in 10,000, depending on the diagnostic criteria and stimulation test thresholds used. Therefore, the rising prevalence of pediatric growth hormone deficiency (GHD) drives the ngenla industry.

Key Players In The Global Ngenla Market

Major companies operating in the ngenla market are Pfizer Inc.

Global Ngenla Market Trends and Insights

The key trend in the Ngenla market is emphasizing advancements such as long-acting growth hormone therapies, enhancing treatment adherence, and delivering better overall outcomes for pediatric and adult patients with growth hormone deficiency. Long-acting growth hormone therapies are designed to provide sustained hormone release, reducing the frequency of injections and improving patient compliance in treating growth hormone deficiencies. For instance, in June 2023, Pfizer Inc., a US-based biopharmaceutical company, and OPKO Health Inc., a US-based medication company, received US Food and Drug Administration (FDA) approval for NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog. NGENLA is indicated for treating pediatric patients aged three years and older who have growth failure due to insufficient endogenous growth hormone secretion.

What Are Latest Mergers And Acquisitions In The Ngenla Market?

In July 2024, OPKO Health, Inc., a US-based biopharmaceutical and diagnostics company, partnered with HealthCare Royalty (HCRx) for non-dilutive note purchase agreements. This agreement is secured by OPKO’s profit share payments from Pfizer related to NGENLA, a treatment for pediatric growth hormone deficiency. The deal allows OPKO to retain a substantial portion of these profit shares in the short term while also providing potential long-term financial benefits. HealthCare Royalty (HCRx) is a US-based royalty acquisition company.

Regional Insights

North America was the largest region in the ngenla market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Ngenla Market?

The ngenla market consists of sales of prefilled injection pens and somatrogon solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ngenla Market Report 2026?

The ngenla market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ngenla industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.